Agenus is an immuno-oncology company designed to deliver innovation with speed for patients with cancer. We have a unique portfolio of antibodies, vaccines, cell therapies (through our AgenTus Therapeutics subsidiary) and adjuvants designed to treat cancers with optimal combinations. In addition to our broad portfolio, we have an accomplished team of scientists, novel technology platforms and end-to-end capabilities from new target discovery to GMP manufacturing. We believe that combination therapies and a deep understanding of each patientâs cancer will be key drivers of success in substantially expanding the patient population benefiting from current immuno-oncology therapies. At Agenus, we believe we have assembled the capabilities to bring curative treatments to patients. Source
No articles found.
Catasys has contracted with leading national, regional and local health insurance ...
Catasys has contracted with leading national, r...
Johnson & Johnson engages in the research and development, manufacture, and sale o...
Johnson & Johnson engages in the research and d...
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedica...
Global Blood Therapeutics, Inc. (GBT) is a clin...
BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autolog...
BrainStorm (NASDAQ:BCLI) is a biotechnology com...
Chembio is a leading point-of-care diagnostics company focused on detecting and di...
Chembio is a leading point-of-care diagnostics ...
Intersect ENT (NASDAQ: XENT) is a medical technology company dedicated to advancin...
Intersect ENT (NASDAQ: XENT) is a medical techn...
Allogene Therapeutics is a clinical stage biotechnology company pioneering the dev...
Allogene Therapeutics is a clinical stage biote...
Join the National Investor Network and get the latest information with your interests in mind.